These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Characteristics of pediatric C3 glomerulopathy with decreased factor H in 3 cases]. He RJ, Xiao HJ, Wang SX, Guan N, Yao Y, Ding J. Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):939-43. PubMed ID: 23324154 [Abstract] [Full Text] [Related]
24. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G. Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476 [Abstract] [Full Text] [Related]
26. Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. Zanchi C, Locatelli M, Cerullo D, Aumiller V, Corna D, Rottoli D, Eisermann M, Donadelli R, Mousavi M, Noris M, Remuzzi G, Benigni A, Zoja C. J Immunol; 2022 Apr 01; 208(7):1772-1781. PubMed ID: 35277417 [Abstract] [Full Text] [Related]
28. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ. Kidney Int; 2012 Aug 01; 82(4):465-73. PubMed ID: 22673887 [Abstract] [Full Text] [Related]
29. [Complement system regulation and C3 glomerulopathy]. Xiao HJ, He RJ. Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr 18; 45(2):323-6. PubMed ID: 23591359 [Abstract] [Full Text] [Related]
32. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy. Madden B, Singh RD, Haas M, Palma LMP, Sharma A, Vargas MJ, Gross L, Negron V, Nate T, Charlesworth MC, Theis JD, Nasr SH, Nath KA, Fervenza FC, Sethi S. Kidney Int; 2024 May 18; 105(5):1077-1087. PubMed ID: 38447879 [Abstract] [Full Text] [Related]
33. Characterization of C3 in C3 glomerulopathy. Sethi S, Vrana JA, Fervenza FC, Theis JD, Sethi A, Kurtin PJ, Zhang Y, Smith RJH. Nephrol Dial Transplant; 2017 Mar 01; 32(3):459-465. PubMed ID: 27507892 [Abstract] [Full Text] [Related]
37. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes. Wong EKS, Marchbank KJ, Lomax-Browne H, Pappworth IY, Denton H, Cooke K, Ward S, McLoughlin AC, Richardson G, Wilson V, Harris CL, Morgan BP, Hakobyan S, McAlinden P, Gale DP, Maxwell H, Christian M, Malcomson R, Goodship THJ, Marks SD, Pickering MC, Kavanagh D, Cook HT, Johnson SA, MPGN/DDD/C3 Glomerulopathy Rare Disease Group and National Study of MPGN/DDD/C3 Glomerulopathy Investigators. Clin J Am Soc Nephrol; 2021 Nov 01; 16(11):1639-1651. PubMed ID: 34551983 [Abstract] [Full Text] [Related]
38. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy). Prasto J, Kaplan BS, Russo P, Chan E, Smith RJ, Meyers KE. Eur J Pediatr; 2014 Jun 01; 173(6):767-72. PubMed ID: 24384791 [Abstract] [Full Text] [Related]